GOSS
Price
$0.14
Change
-$0.03 (-17.65%)
Updated
Jul 13 closing price
Capitalization
70.44M
29 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$123.94
Change
+$0.04 (+0.03%)
Updated
Jul 13 closing price
Capitalization
9.81B
24 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GOSS vs NUVL

GOSS vs NUVL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GOSS vs. NUVL commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Buy and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (GOSS: $0.17 vs. NUVL: $123.90)
Brand notoriety: GOSS and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 89% vs. NUVL: 41%
Market capitalization -- GOSS: $70.44M vs. NUVL: $9.81B
GOSS [@Biotechnology] is valued at $70.44M. NUVL’s [@Biotechnology] market capitalization is $9.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 5 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 3 bearish.
  • NUVL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than NUVL.

Price Growth

GOSS (@Biotechnology) experienced а -2.02% price change this week, while NUVL (@Biotechnology) price change was +0.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +7.30%, and the average quarterly price growth was +1806.57%.

Reported Earning Dates

GOSS is expected to report earnings on Aug 11, 2026.

NUVL is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($9.81B) has a higher market cap than GOSS($70.4M). NUVL YTD gains are higher at: 23.213 vs. GOSS (-95.352). GOSS has higher annual earnings (EBITDA): -168.59M vs. NUVL (-438.9M). NUVL has more cash in the bank: 1.29B vs. GOSS (99.2M). GOSS has higher revenues than NUVL: GOSS (55.5M) vs NUVL (0).
GOSSNUVLGOSS / NUVL
Capitalization70.4M9.81B1%
EBITDA-168.59M-438.9M38%
Gain YTD-95.35223.213-411%
P/E RatioN/AN/A-
Revenue55.5M0-
Total Cash99.2M1.29B8%
Total Debt203MN/A-
FUNDAMENTALS RATINGS
GOSS: Fundamental Ratings
GOSS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
23

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GOSSNUVL
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 18 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMCQX15.31N/A
N/A
GMO US Equity VI
FEYAX33.97N/A
N/A
Fidelity Advisor Asset Manager 85% A
NSNRX57.68N/A
N/A
Neuberger Small Cap Growth R3
WOFNX67.49N/A
N/A
Allspring Opportunity Inst
JMIGX34.69N/A
N/A
Jacob Discovery Fd Instl

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-15.09%
LITS - GOSS
46%
Loosely correlated
-6.36%
APVO - GOSS
41%
Loosely correlated
+5.33%
NUVL - GOSS
39%
Loosely correlated
+0.03%
IDYA - GOSS
38%
Loosely correlated
-2.27%
XNCR - GOSS
38%
Loosely correlated
-5.62%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.03%
MLTX - NUVL
49%
Loosely correlated
+0.25%
XNCR - NUVL
42%
Loosely correlated
-5.62%
PCVX - NUVL
41%
Loosely correlated
-2.03%
PTGX - NUVL
39%
Loosely correlated
-1.16%
GOSS - NUVL
39%
Loosely correlated
-15.09%
More